Patients with Prehypertension - Do we have Enough Evidence to Treat them?

被引:4
|
作者
Marta, Michalska [1 ]
Zanchetti, Alberto [2 ]
Wong, Nathan D. [3 ]
Malyszko, Jolanta [4 ]
Rysz, Jacek [1 ]
Banach, Maciej [1 ]
机构
[1] Med Univ Lodz, Dept Hypertens, PL-90549 Lodz, Poland
[2] Univ Milan, Ist Auxol Italiano, Milan, Italy
[3] Univ CA, Dept Med, Irvine, CA USA
[4] Med Univ, Dept Nephrol & Transplantol, Bialystok, Poland
关键词
Blood pressure; cardiovascular risk; high normal blood pressure; hypertension; prehypertension; risk stratification; EXPERT CONSENSUS DOCUMENT; NORMAL BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE RISK; CONVERTING-ENZYME-INHIBITOR; JOINT NATIONAL COMMITTEE; TYPE-2; DIABETIC-PATIENTS; LIFE-STYLE MODIFICATION; METABOLIC SYNDROME; ARTERIAL STIFFNESS; HEART-DISEASE;
D O I
10.2174/15701611113119990126
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In 2003, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure established a definition of a new category of BP levels called 'prehypertension' (preHT) that included individuals with a systolic BP of 120-139 mm Hg or a diastolic BP of 80-89 mm Hg. Patients with preHT were considered to be at increased risk for progression to hypertension and in individuals with BP in the range 130/80 to 139/89 mmHg the risk of developing hypertension was twice as high as in subjects with lower values. Still then there has been a large debate whether the introduction of preHT was based on evidence and as a consequence, it was fully justified. It has been suggested that the term prehypertension may in many subjects create anxiety and a need for unnecessary medical visits and examinations. This group of patients is also very heterogeneous and it has been pointed out that subdividing preHT group into individuals with normal BP and high normal BP would much better correspond to the continuum of BP risk for CV disease. Finally, despite some data suggesting the potential benefits of antihypertensive therapy in patients with preHT (high normal BP), there are still no hard evidences on the outcome reduction by giving antihypertensive drugs in these individuals.
引用
收藏
页码:586 / 597
页数:12
相关论文
共 50 条
  • [1] Do we have enough evidence to insist we have IVUS?
    Starkey, IR
    [J]. HEART, 1997, 78 : 30 - 30
  • [2] Colorectal stents: Do we have enough evidence?
    Al Samaraee, Ahmad
    McCallum, Iain J.
    Kenny, Louise
    Isreb, Siddek
    MacDougall, Louise
    Hayat, Mumtaz
    Kelly, Seamus
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2011, 9 (08) : 595 - 599
  • [3] DO WE HAVE ENOUGH EVIDENCE BASED SEXUAL TREATMENT FOR CANCER PATIENTS?
    Nesher, Peleg S.
    [J]. JOURNAL OF SEXUAL MEDICINE, 2020, 17 (06): : S218 - S218
  • [4] Do we have enough?
    Horvath, Istvan T.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [5] Do we have enough evidence for approval of nadofaragene firadenovec?
    Akand, Murat
    Van der Aa, Frank
    Joniau, Steven
    [J]. MINERVA UROLOGY AND NEPHROLOGY, 2022, 74 (05): : 646 - 647
  • [6] How will we know when we have enough of them?
    Gilmore, WF
    [J]. AMERICAN SCIENTIST, 2003, 91 (02) : 98 - 98
  • [7] Do we have enough 'injidents"?
    Adams, J
    [J]. BRITISH JOURNAL OF GENERAL PRACTICE, 2002, 52 (479): : 454 - +
  • [8] Evidence for health policy in India: do we have enough data?
    Babu, Giridhara R.
    [J]. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2012, 105 (09) : 365 - 365
  • [9] Cap-assisted endoscopy: Do we have enough evidence?
    Frieling, Thomas
    [J]. ENDOSCOPY INTERNATIONAL OPEN, 2018, 6 (10) : E1224 - E1226
  • [10] Do we have enough evidence for expanding the indications of ESD for EGC?
    Lee, Hang Lak
    Choi, Chang Hwan
    Cheung, Dae Young
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (21) : 2597 - 2601